Abstract
Procoagulant membrane microparticles can be released from activated or apoptotic cells in response to various environmental stimuli. The aim of this study was to investigate the presence of microparticles in Crohn’s disease and to assess their variations after infliximab therapy. We compared the levels of circulating microparticles in 38 patients with Crohn’s disease, 16 patients with ulcerative colitis, 7 patients with infectious colitis, and 17 control subjects. The evolution of microparticle levels was assessed after infliximab therapy in 13 patients with Crohn’s disease. Circulating microparticle levels were elevated in patients with Crohn’s disease (9.31 ± 0.66 nmol/L phosphatidylserine equivalent [PS Eq]) or infectious colitis (10.71 ± 0.92 nmol/L PS Eq) compared to patients with ulcerative colitis (5.75 ± 0.59 nmol/L PS Eq) and control subjects (4.06 ± 0.37 nmol/L PS Eq) (P = 0.001). Infliximab induced a significant diminution of the amounts of circulating microparticles, from 10.33 ± 1.20 to 6.45 ± 0.90 nmol/L PS Eq (P = 0.002). Generation of circulating microparticles occurs in Crohn’s disease; infliximab induces significant diminution. Release of microparticles could be linked to the type of inflammatory response underlying Crohn’s disease.
Article PDF
Similar content being viewed by others
References
Podolsky DK: Inflammatory bowel disease. N Engl J Med 347:417–429, 2002
Lam A, Borda IT, Inwood MJ, Thomson S: Coagulation studies in ulcerative colitis and Crohn’s disease. Gastroenterology 68:245–251, 1975
Lake AM, Stauffer JQ, Stuart MJ: Hemostatic alterations in inflammatory bowel diseases. Am J Dig Dis 23:897–902, 1978
Edwards RL, Levine JB, Green R, Duffy M, Mathews E, Brande W, Rickles FR: Activation of blood coagulation in Crohn’s disease: Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology 92:329–337, 1987
Simi M, Leardi S, Tebano MT, Castelli M, Costantini FM, Speranza V: Raised plama concentrations of platelet factor 4 or α for Crohn disease. N Engl J Med 337:1029–1035, 1997
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH: Infliximab for the treatment of fistules in patients with Crohn’s disease. N Engl J Med 340:1398–1405, 1999
Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH: Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769, 1999
Lennard-Jones JE: Definition and diagnosis. In Skandia International Symposia: Regional Enteritis (Crohn’s Disease). Stockolm, Nordiska Bokhandlen’s Förlag, 1971, pp 105–112
van Hees PAM, van Helten PH, van Lier HJJ, van Tongeren JHM: An index of inflammatory activity in patients with Crohn’s disease. Gut 21:279–286, 1980
Truelove SC, Witts LJ: Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br J Med 2:1041–1048, 1988
Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM: Scott syndrome characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 87:1409–1415, 1996
Dubois T, Mira JP, Feliers D, Solito E, Russo-Marie F, Oudinet JP: Annexin V activity inhibits protein kinase C activity via a mechanism of phospholipid sequestration. Biochem J 330:1277–1282, 1998
Pigault C, Follenius-Wund A, Schmutz M, Freyssinet JM, Brisson A: Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 236:199–208, 1994
Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207–2216, 1992
Fourcade O, Simon MF, Viodé C, Rugani N, Leballe F, Ragad A, Fournié B, Sarda L, Chap H: Secretory phospholipase A2, generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80:919–927, 1995
Tabibzadeh SS, Kong QF, Kapur S: Passive acquisition of leukocyte proteins is associated with changes in phosphorylation of cellular proteins and cell-cell adhesion properties. Am J Pathol 145:930–940, 1994
Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F: Immunoregulation in the gut: success and failures in human disease. Gut 50(Suppl III):iii60–iii-64, 2002
Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F: Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169–1178, 1997
Fuss IJ, Neurath M, Boivirant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of INF-γ whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261–1270, 1996
Agnholt J, Kaltoft K: Infliximab downregulates interferon-gamma production inactivated gut T-lymphocytes from patients with Crohn’s disease. Cytokine 15:212–222, 2001
Targan SR: Biology of inflammation in Crohn’s disease: Mechanisms action of anti-TNF-α therapy. Can J Gastroenterol 14(Suppl C):13C–16C, 2000
MacDonald TT, Monteleone G, Pender SL: Recent developments in immunology of inflammatory bowel disease. Scand J Immunol 51:2–9, 2000
Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205, 1998
van Deventer SJH: Tumour necrosis factor and Crohn’s disease. Gut 40:443–448, 1997
Reinecker H-C, Steffen M, Witthoeft T, Pflueger L, Schreiber S, MacDermott RP, Raedler A: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 94:174–181, 1993
Louis E, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G, Croes F, Dupont P, Davin L, Omri S, Rutgeerts P, Belaiche J: Tumour necrosis factor (TNF) gene polymorphism in Crohn’s disease (CD): Influence on disease behaviour ? Clin Exp Imunol 119:64–68, 2000
Eckmann L, Kagnoff MF: Cytokines in host defense against salmonella. Microbes Infect 3:119–200, 2001
Abram M, Vukovic D, Wraber B, Doric M: Plasma cytokine response in mice with bacterial infection. Mediat Inflam 9:229–234, 2000
Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C: Platelets trigger a CD40-dependent inflammatory response in microvasculature of inflammatory bowel disease patients. Gastroenterology 124:1249–1264, 2003
Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B: Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 17:476–478, 2003
Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticles P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197:1585–1598, 2003
Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH, Schaub RG, McEver RP, Wagner DD: Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 9:1020–1025, 2003
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chamouard, P., Desprez, D., Hugel, B. et al. Circulating Cell-Derived Microparticles in Crohn’s Disease. Dig Dis Sci 50, 574–580 (2005). https://doi.org/10.1007/s10620-005-2477-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2477-0